ELCC 2025: Latest in EGFR positive NSCLC

Adding durvalumab to neoadjuvant chemotherapy maintains quality of life in resectable NSCLC

Digital pathology superior to manual SP263 PD-L1 TC scoring for stage II-IIIA high PD-L1 expression NSCLC

Taletrectinib superior to crizotinib in ROS1-positive non-small cell lung cancer

Perioperative durvalumab in addition to neoadjuvant chemotherapy shows positive results in patients with stage IIIa(N2) NSCLC

Pembrolizumab plus cCRT continue to demonstrate antitumour activity in advanced NSCLC

Treatment with BAY 2927088 led to durable responses in patients previously treated HER2-mutant NSCLC

Dermatologic adverse events in the treatment of NSCLC with amivantamab plus lazertinib significantly reduced

Consolidation durvalumab after cCRT shows decreased disease progression in LS-SCLC

Subcutaneous pembrolizumab is a viable treatment option for mNSCLC